19.1 C
New York
Thursday, June 13, 2024

Third member of prestigious FDA panel resigns over approval of Biogen’s Alzheimer’s drug

  • A third member of a key Food and Drug Administration advisory panel has resigned over the agency's controversial decision to approve Biogen's new Alzheimer's drug, Aduhelm, CNBC has learned.
  • Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School, said the agency's decision on Biogen "was probably the worst drug approval decision in recent U.S. history," according to his resignation letter obtained by CNBC.

In this article

Related Articles

Latest Articles